The Food and Drug Administration (FDA) has approved MP Diagnostics HTLV Blot 2.4, the first supplemental test for Human T-Cell Lymphotropic Virus-I/II (HTLV-I/II).
The HTLV Blot 2.4 is a qualitative enzyme immunoassay test indicated for use as a more specific test for human serum or plasma specimens that have previously tested positive on a licensed HTLV-I/II blood donor screening test. It is meant to confirm HTLV infection and to differentiate between HTLV-I and HTLV-II.
There are currently two FDA-licensed screening tests for HTLV-I/II used in testing blood samples from a donor. If the sample tests positive, the HTLV Blot 2.4 can distinguish which virus type is causing the infection and can provide further information to the donor.
For more information visit FDA.gov.